Skip Navigation


Annals of Oncology Advance Access originally published online on June 21, 2005
Annals of Oncology 2005 16(10):1710-1711; doi:10.1093/annonc/mdi305
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
16/10/1710    most recent
mdi305v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Ferrucci, P. F.
Right arrow Articles by Martinelli, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ferrucci, P. F.
Right arrow Articles by Martinelli, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society for Medical Oncology

Letter to the Editor

Cerebrospinal fluid diffusion of Zevalin® after high-activity treatment and stem cell support in a patient affected by diffuse large B-cell non-Hodgkin's lymphoma with central nervous system involvement

The first 10% of the full text of this article appears below.

Current treatment of central nervous system non-Hodgkin's lymphomas (CNS NHLs) is restricted to limited therapeutic options, which include radiotherapy, systemic chemotherapy and intrathecal injections of cytotoxic drugs. We present a clinical case of a heavily pretreated patient affected by cerebral and systemic lymphoma enrolled in a phase I–II study of high-dose Zevalin with autologous stem cell support.

Zevalin is an anti-CD20 monoclonal antibody of murine origin labelled with an yttrium 90 (90Y) particle. At a standard activity level . . . [Full Text of this Article]

P. F. Ferrucci1,*, A. Vanazzi1, G. Tesoriere2, M. Ferrari2, M. Bartolomei2, P. Rocca2, M. Cremonesi2, G. Paganelli2 and G. Martinelli1

1 Hematoncology Division, 2 Nuclear Medicine Division and 3 Pathology and Laboratory Medicine Division at the European Institute of Oncology, Milan, Italy

* E-mail: pier.ferrucci@ieo.it


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Neuro Oncol DukeHome page
S. Maza, P. Kiewe, D. L. Munz, A. Korfel, B. Hamm, K. Jahnke, and E. Thiel
First report on a prospective trial with yttrium-90-labeled ibritumomab tiuxetan (Zevalin) in primary CNS lymphoma
Neuro-oncol, January 1, 2009; 11(4): 423 - 429.
[Abstract] [Full Text] [PDF]